On December 3, 2019, the U.S. Food and Drug Administration approved Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) as a first treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK changes. This approval is based on the Phase III IMpower130 study which showed that Tecentriq in combination with chemotherapy helped people live significantly longer than chemotherapy alone. This approval offers a new combination therapy option to improve survival [...]
FDA Approves Genentech’s Rozlytrek (entrectinib) for ROS1 Non-Small Cell Lung Cancer (NSCLC) and NTRK-Driven Tumors
On August 15, 2019 the U.S. Food and Drug Administration approved Rozlytrek (entrectinib) for the treatment of patients with ROS1-positive, metastatic non-small cell lung cancer. It was also simultaneously approved for the treatment of patients with any solid tumor that is NTRK fusion-positive, following progression on other therapies. This approval offers a new targeted therapy option for patients with both of these rare mutations and is only the third time that the FDA has approved a targeted therapy for any [...]
The GO2 Foundation for Lung Cancer is honored to announce that on May 2 two of our programs received Your Cancer’s Cancer Community (C2) Awards. These awards celebrate “the unsung heroes of cancer care” – individuals and organizations that advance cancer care and work to improve the lives of those living with the disease. The Centers of Excellence (COE) program received Your Cancer’s C2 Catalyst for Care Award. This category recognized nominees making the experience of cancer care easier for [...]
Last year was an exciting year for lung cancer research with more U.S. Food and Drug Administration (FDA) approval decisions relevant to lung cancer than ever before. So, what can we expect for 2019? Another eventful year with researchers studying how to best give the approved drugs (i.e. what order and combinations) as well as expanding the options with more types of therapies. IMMUNOTHERAPY IN NON-SMALL CELL LUNG CANCER First, there is the rapidly growing field of immunotherapy. We have [...]
The Food and Drug Administration (FDA) approved atezolizumab (TECENTRIQ®), an immunotherapy drug, in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations. This is the first four drug combination treatment approved for lung cancer. Click here to learn more.